Float Short %

29.19

Margin Of Safety %

Put/Call OI Ratio

0.35

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.04

EPS This/Next Y

2.91

Price

8.28

Target Price

34.33

Analyst Recom

Performance Q

-4.61

Relative Volume

1.21

Beta

0.67

Ticker: AVXL

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-05-09	AVXL	8.26	0.39	0.06	62663
2025-05-12	AVXL	8.53	0.38	0.28	63348
2025-05-13	AVXL	8.2	0.38	0.34	63578
2025-05-14	AVXL	8.17	0.38	0.18	63986
2025-05-15	AVXL	8.38	0.38	0.22	64077
2025-05-16	AVXL	8.31	0.38	0.42	64231
2025-05-19	AVXL	8.44	0.38	0.30	57574
2025-05-20	AVXL	7.53	0.37	0.22	58247
2025-05-21	AVXL	7.77	0.37	0.14	61334
2025-05-22	AVXL	7.68	0.37	0.10	62629
2025-05-23	AVXL	7.53	0.36	0.43	63122
2025-05-27	AVXL	7.36	0.36	0.07	63800
2025-05-28	AVXL	7.56	0.35	0.28	64973
2025-05-29	AVXL	7.63	0.35	0.15	65188
2025-05-30	AVXL	7.51	0.35	0.43	65321
2025-06-02	AVXL	7.55	0.35	0.57	65648
2025-06-03	AVXL	7.83	0.35	0.24	65695
2025-06-04	AVXL	7.72	0.35	0.01	65795
2025-06-05	AVXL	7.77	0.35	0.22	65980
2025-06-06	AVXL	8.27	0.35	0.56	66294
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-05-09	AVXL	8.25	-15.4	-	-0.65
2025-05-12	AVXL	8.55	-15.4	-	-0.65
2025-05-13	AVXL	8.10	-15.4	-	-0.65
2025-05-14	AVXL	8.16	-15.4	-	-0.65
2025-05-15	AVXL	8.37	-3.6	-	-0.65
2025-05-16	AVXL	8.32	-3.6	-	-0.56
2025-05-19	AVXL	8.44	-3.6	-	-0.56
2025-05-20	AVXL	7.53	-3.6	-	-0.56
2025-05-21	AVXL	7.76	-3.6	-	-0.56
2025-05-22	AVXL	7.68	-3.6	-	-0.56
2025-05-23	AVXL	7.53	-3.6	-	-0.56
2025-05-27	AVXL	7.37	-3.6	-	-0.56
2025-05-28	AVXL	7.57	-3.6	-	-0.56
2025-05-29	AVXL	7.63	-3.6	-	-0.56
2025-05-30	AVXL	7.53	-3.6	-	-0.56
2025-06-02	AVXL	7.55	-3.6	-	-0.56
2025-06-03	AVXL	7.84	-3.6	-	-0.56
2025-06-04	AVXL	7.72	-3.6	-	-0.56
2025-06-05	AVXL	7.78	-3.6	-	-0.56
2025-06-06	AVXL	8.28	-3.6	-	-0.56
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-05-09	AVXL	0.00	10.99	29.09
2025-05-12	AVXL	0.00	12.95	28.46
2025-05-13	AVXL	0.00	12.95	28.46
2025-05-14	AVXL	0.00	12.95	28.46
2025-05-15	AVXL	0.00	12.95	28.46
2025-05-16	AVXL	0.00	12.95	28.46
2025-05-19	AVXL	0.00	10.51	28.46
2025-05-20	AVXL	0.00	10.51	28.46
2025-05-21	AVXL	0.00	10.51	28.46
2025-05-22	AVXL	0.00	10.51	28.46
2025-05-23	AVXL	0.00	10.51	28.46
2025-05-27	AVXL	0.00	5.40	28.46
2025-05-28	AVXL	0.00	5.40	29.19
2025-05-29	AVXL	0.00	5.40	29.19
2025-05-30	AVXL	0.00	5.40	29.19
2025-06-02	AVXL	0.00	5.99	29.19
2025-06-03	AVXL	0.00	5.99	29.19
2025-06-04	AVXL	0.00	5.99	29.19
2025-06-05	AVXL	0.00	5.99	29.19
2025-06-06	AVXL	0.00	5.99	29.19
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

Institutional Transactions

5.99

Beta

0.67

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

73.7

Max Drawdown 5-Year %

-88.3

Target Price

34.33

P/E

Forward P/E

5.87

PEG

P/S

P/B

7.07

P/Free Cash Flow

EPS

-0.56

Average EPS Est. Cur. Y

-0.56

EPS Next Y. (Est.)

2.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.21

Return on Equity vs Sector %

-71.3

Return on Equity vs Industry %

-53.3

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.09

EBIT Estimation

Anavex Life Sciences Corp.

Sector: Healthcare

Industry: Biotechnology

Employees: 42

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

stock quote shares AVXL – Anavex Life Sciences Corp. Stock Price stock today

news today AVXL – Anavex Life Sciences Corp. stock forecast ,stock prediction 2023 2024 2025

marketwatch AVXL – Anavex Life Sciences Corp. yahoo finance google finance

stock history AVXL – Anavex Life Sciences Corp. invest stock market

stock prices AVXL premarket after hours

ticker AVXL fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: AVXL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y